Search results
States struggle to help patients navigate insurance hurdle known as ‘step therapy’
North Dakota Monitor via Yahoo News· 2 days agoCassidy Yermal, 32, began experiencing debilitating migraines when she was 17 years old. As a...
Jude Bellingham fans discuss hyperpigmentation over footballer's appearance
Yahoo Life UK· 6 days agoRead more about skin conditions: How a healthy gut microbiome can give you better winter skin (Yahoo...
9 Face-Lifting Skincare Products Dermatologists Recommend For Fast, Visible Results This Summer
SheFinds via Yahoo News· 5 days agoIf you’ve become aware of the onset of fine lines and wrinkles or have been considering the...
Doctors Share What Foods You Should Be Eating To Look 'Healthier And More Youthful'—Plus Which Foods...
SheFinds via Yahoo News· 7 days agoAs we welcome summer weather, doctors and skincare experts stress that it’s crucial to keep yourself...
Why Diabetes, High Blood Pressure and More Conditions Can Make Heatwaves Dangerous
CNET· 3 days agoA heat wave has stifled parts of the US this week, with people across the Midwest and Northeast...
Can High Cortisol Levels Cause Weight Gain?
MediaFeed via AOL· 6 days agoElevated cortisol levels can trigger various physical, emotional and behavioral symptoms. (These can indicate other health concerns, though, so keep that...
TREMFYA® (guselkumab) studies underscore its potential to be the only IL-23 inhibitor to offer both...
Morningstar· 5 days agoJohnson & Johnson (NYSE: JNJ) today announced positive topline results from the pivotal Phase 3 GRAVITI investigational study of TREMFYA® (guselkumab) subcutaneous (SC) induction therapy in ...
Here Comes the Sun: We Are Your Summer Skincare Experts
Lancaster Online· 5 days agoSummer is finally here and, for most of us, that means more time in the sun - whether it’s relaxing...
U.S. FDA Approves SKYRIZI® (risankizumab-rzaa) for Ulcerative Colitis, Expanding AbbVie's Portfolio...
Morningstar· 7 days agoApproval supported by two Phase 3 clinical trials that evaluated SKYRIZI® for the treatment of moderate to severe ulcerative colitis: a 12-week induction study, INSPIRE,1 and a 52-week maintenance study, COMMAND2Data showed that clinical remission,
Johnson & Johnson submits application to U.S. FDA seeking approval of TREMFYA® (guselkumab) for the...
Morningstar· 5 days agoJohnson & Johnson (NYSE: JNJ) today announced the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) seeking approval of TREMFYA ...